Fluicell AB Logo

Fluicell AB

Developing bioprinted tissues for regenerative medicine and advanced drug screening.

FLUI | ST

Overview

Corporate Details

ISIN(s):
SE0010831321 (+1 more)
LEI:
549300R9LVFVFDTW5Y96
Country:
Sweden
Address:
Flöjelbergsgatan 8c, 431 37 Mölndal
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Fluicell AB is a biotechnology company specializing in single-cell biology and high-precision tissue engineering. The company develops solutions for regenerative medicine and drug screening through its groundbreaking Nexocyte™ platform, which is based on its patented, high-resolution Biopixlar™ single-cell bioprinting technology. Fluicell's primary focus is creating precision-engineered, transplantable tissues to treat diseases with significant unmet needs, with an initial goal to develop a cure for type 1 diabetes. In parallel, the Nexocyte platform generates advanced tissue models for pharmaceutical partners to enhance drug screening, particularly for cardiac and kidney toxicity. The company also commercializes a portfolio of research tools, including the BioPen® and Dynaflow® systems, that support single-cell research globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Fluicell AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Fluicell AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
OPTIBIOTIX HEALTH PLC Logo
Develops microbiome-modulating ingredients and supplements to manage chronic lifestyle diseases.
United Kingdom OPTI
OXFORD BIODYNAMICS PLC Logo
Develops precision blood tests using 3D genomics for cancer diagnosis and therapy guidance.
United Kingdom OBD
Pharnext Logo France ALPHA
PHYSIOMICS PLC Logo
De-risks oncology drug development for pharma/biotech using modeling and simulation.
United Kingdom PYC
PILA PHARMA AB Logo
Clinical-stage biopharma developing a first-in-class oral drug for diabetes and obesity.
Sweden PILA
POOLBEG PHARMA PLC Logo
AI-led biopharma developing drugs for high-need diseases like CRS and metabolic disorders.
United Kingdom POLB
PROTEOME SCIENCES PLC Logo
CRO providing proteomics services & TMT® tags to biopharma for drug discovery & biomarkers.
United Kingdom PRM
PROVEXIS PLC Logo
Develops & licenses Fruitflow®, a patented ingredient for heart health in food & supplements.
United Kingdom PXS
Develops uncopiable atomic fingerprints for anti-counterfeiting, verifiable by smartphone.
United Kingdom N/A
QUANTUM BLOCKCHAIN TECHNOLOGIES PLC Logo
R&D firm using AI and quantum computing to create efficient technologies for Bitcoin mining.
United Kingdom QBT

Talk to a Data Expert

Have a question? We'll get back to you promptly.